Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Oklahoma Healthcare Wire.
Press releases published on May 30, 2025
Hydreight Reports 34% Year-Over-Year Q1 Revenue Growth, Improvement in Bottom Line Results, and Delivers Strong Performance Across Verticals
GlobeNewswire
·
May 30, 2025
“It was an outstanding quarter. We exceeded our Q1 projections with approximately 34% YOY growth from our first two verticals, a clear sign that our strategy is working. We also secured new customers for VSDHOne, positioning us strongly to hit our year-end …
Early Warning Press Release Respecting the Acquisition of Common Shares of RAMM PHARMA Corp.
GlobeNewswire
·
May 30, 2025
TORONTO, May 30, 2025 (GLOBE NEWSWIRE) -- Jack Burnett ("CEO") today announced that he has filed an early warning report (the "Early Warning Report") under National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider …
Celularity Receives Nasdaq Notice Regarding Form 10-Q
GlobeNewswire
·
May 30, 2025
FLORHAM PARK, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a cellular and regenerative medicine company, today announced that on May 28, 2025, Nasdaq notified the Company that it did not timely file …
COSCIENS Biopharma Inc. Reconstitutes Board for Benefit of Shareholders
GlobeNewswire
·
May 30, 2025
Reconstituted Board to Revitalize COSCIENS TORONTO, May 30, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI; TSX: CSCI) today announced that it has entered into a resolution agreement (the “Resolution Agreement”) with Goodwood Inc., Goodwood …
Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors
GlobeNewswire
·
May 30, 2025
SAN DIEGO, May 30, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immunotherapies to …
Publication relating to transparency notifications
GlobeNewswire
·
May 30, 2025
REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), May 30, 2025, 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large …
Publication relative à des notifications de transparence
GlobeNewswire
·
May 30, 2025
INFORMATION RÉGLEMENTÉE Publication relative à des notifications de transparence Mont-Saint-Guibert (Belgique), le 30 mai 2025, 22:30h CET / 16:30h ET – Conformément à l'article 14 de la loi du 2 mai 2007 relative à la publicité des participations …
Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights
GlobeNewswire
·
May 30, 2025
Company continues to progress both REYOBIQ™ radiotherapeutic clinical trials and CNSide® CSF assay platform launch readiness HOUSTON, May 30, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage …
NurExone Announces Clinical Trial Plans for Acute Spinal Cord Injury Therapy at Annual Meeting of American Spinal Injury Association
GlobeNewswire
·
May 30, 2025
TORONTO and HAIFA, Israel, May 30, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) is pleased to announce that Professor Nahshon Knoller M.D., senior clinical advisor to the Company, will …
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
May 30, 2025
VANCOUVER, British Columbia and BOSTON, May 30, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for …
Kymera Therapeutics to Announce KT-621 Phase 1 Healthy Volunteer Trial Results on June 2, 2025
GlobeNewswire
·
May 30, 2025
WATERTOWN, Mass., May 30, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will announce results from …
Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks Partnerships
GlobeNewswire
·
May 30, 2025
WARREN, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today provided stockholders with a detailed overview of its artificial intelligence initiative, Tevogen.AI™. Tevogen.AI™ aims to integrate …
America’s Blood Centers and ACS Stop the Bleed Announce New National Collaboration
GlobeNewswire
·
May 30, 2025
Washington, DC, May 30, 2025 (GLOBE NEWSWIRE) -- America’s Blood Centers (ABC), the national organization of community-based, independent blood centers that supply 60 percent of the nation’s blood supply, and the American College of Surgeons (ACS) Stop the …
Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics
GlobeNewswire
·
May 30, 2025
MIAMI, May 30, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity …
PESG Research Report: Revolutionary Surgical Infection Prevention: PolyPid’s D-PLEX100 Approaches Critical Phase 3 Data Readout
GlobeNewswire
·
May 30, 2025
New York, May 30, 2025 (GLOBE NEWSWIRE) -- PESG Research is releasing a report today examining PolyPid Ltd.*, an innovative late-stage biopharmaceutical company developing revolutionary localized drug delivery technologies for surgical infection …
Legend Senior Living® Grows Portfolio Across Kansas, Colorado, and Pennsylvania
GlobeNewswire
·
May 30, 2025
WICHITA, Kan., May 30, 2025 (GLOBE NEWSWIRE) -- Legend Senior Living, a national senior housing provider headquartered in Wichita, Kansas, has announced it will assume management of four additional communities, expanding its growing portfolio. The …
Canadian Vaping Association Highlights Plans to Reduce Youth Vaping Rates on World Vape Day
GlobeNewswire
·
May 30, 2025
Ottawa, ON, May 30, 2025 (GLOBE NEWSWIRE) -- On World Vape Day, the Canadian Vaping Association (CVA) celebrates the continued decline in youth vaping rates, as reported in Statistics Canada’s 2025 Canadian Health Survey on Children and Youth (published …
PharmAla Biotech Warns Against Fake Products Claiming to be Made by PharmAla
GlobeNewswire
·
May 30, 2025
TORONTO, May 30, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA ( …
Specific Health Guidance Service Utilizing the "Lav" Healthcare App: Surpassed 100 cumulative contracted companies and 10,000 cumulative supported individuals!
GlobeNewswire
·
May 30, 2025
TOKYO, May 30, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) ("MEDIROM," "we,” “us” or “our”), a holistic healthcare company based in Japan, announces that its subsidiary, MEDIROM MOTHER Labs, Inc., has surpassed 100 …
Processa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting
GlobeNewswire
·
May 30, 2025
HANOVER, Md., May 30, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage pharmaceutical company focused on developing the next generation cancer therapies with improved efficacy and safety, today announced the …